FOLH1 and posterior cortical atrophy: The earliest application of Lutetium within the treatment pathway of PCa was investigated in the phase I/II LuTectomy trial with the administration of [177Lu]Lu-PSMA-617 in a neoadjuvant setting for high-risk localized PCa 6 weeks prior to RP.